Skip to main content
OpenTrials
Completed

NCT Number: NCT04634812

Mass Balance Study of KBP-5074 in Healthy Male Subjects

This is a Phase 1, open-label, nonrandomized, single-dose mass balance and metabolite identification study in healthy male subjects.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–55 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

Covance Clinical Research Unit Inc.

Madison, Wisconsin, 53704, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Males, of any race, between 18 and 55 years of age, inclusive, at screening.
  • Body mass index between 18.0 and 32.0 kg/m2, inclusive, at screening.
  • In good health, determined by no clinically significant findings from medical history, physical examination (assessed only at check-in), 12-lead ECG, vital sign measurements, and clinical laboratory evaluations (congenital nonhemolytic hyperbilirubinemia [eg, suspicion of Gilbert's syndrome based on total and direct bilirubin] is not acceptable) at screening and check-in as assessed by the investigator (or designee).
  • History of a minimum of 1 bowel movement per day.

Exclusion criteria

  • Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, psychiatric, or other disorder, as determined by the investigator (or designee).
  • History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy and hernia repair will be allowed; cholecystectomy will not be allowed).
  • Positive urine drug screen, including cotinine, at screening; positive alcohol test result or positive urine drug screen, including cotinine, at check-in.
  • Use of any drugs or substances known to be strong or moderate inhibitors or inducers of cytochrome P450 (CYP)3A4 or P-glycoprotein substrates within 30 days prior to study drug administration. Medications will be reviewed by the medical monitor to determine acceptability for the study.

Treatment and study plan

KBP-5074

Drug

a single oral dose of [14C]-KBP-5074

Primary outcomes

  1. Mass Balance of KBP-5074

    Time frame: up to 240 hours postdose

    Percentage of total radioactivity recovered in urine and feces following a single dose [14C]-KBP-5074

  2. Pharmacokinetic Parameter: Area under the concentration-time curve from time 0 to infinity (AUC0-∞)

    Time frame: up to 216 hours postdose

    Area under the concentration-time curve from time 0 to infinity (AUC0-∞) - Plasma

  3. Pharmacokinetic Parameter: Area under the plasma concentration time curve from time zero to time of last quantifiable concentration (AUC0-tlast)

    Time frame: up to 216 hours postdose

    Area under the plasma concentration time curve from time zero to time of last quantifiable concentration (AUC0-tlast) - Plasma

  4. Pharmacokinetic Parameter: Time of the maximum observed concentration (Cmax)

    Time frame: up to 216 hours postdose

    Time of the maximum observed concentration (Cmax) - Plasma

Secondary outcomes

  1. Metabolite radioprofiling and identification in plasma, urine and feces

    Time frame: up to 240 hours postdose

    Select plasma, urine, and fecal samples will be processed and subject to metabolite analysis by LC/MS & LC/MS/MS using high-resolution mass spectrometry.

Sponsors and collaborators

Lead sponsor

KBP Biosciences

Industry

Collaborators

  • Covance

Registry information

Official study title

A Phase 1, Open-label, Study of the Absorption, Metabolism, and Excretion of [14C]-KBP-5074 Following a Single Oral Dose in Healthy Male Subjects

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Nov 18, 2020
Registry last updated
Dec 16, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.